MedTrace Logo

The Hemodynamic Effects of PACAP38 After Glibenclamide Administration in Healthy Volunteers

NCT04960657 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2021-07-14

No results posted yet for this study

Summary

To investigate the hemodynamic effects of PACAP38 after glibenclamide administration.

Conditions

Interventions

DRUG

glibenclamide

Oral administration of glibenclamide/placebo. To investigate the role of PACAP38 on cranial arteries in healthy volunteers after glibenclamide/placebo administration .

DRUG

PACAP38

PACAP38 infusion

Sponsors & Collaborators

  • Danish Headache Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-10-20
Primary Completion
2021-03-19
Completion
2021-03-19

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04960657 on ClinicalTrials.gov